Biosimilars in the EU - what have we learned so far?
This article was originally published in SRA
Executive Summary
With the EU set to approve its first two bioisimilar monoclonal antibodies, it is time to look back over the seven years since the first biosimilars were approved. Steffen Thirstrup considers the lessons learnt and examines the outlook in the EU for this new group of biological medicines.